ESLA Stock Overview

A clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. More details

ESLA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Earnings have declined by 39.2% per year over past 5 years

Volatile share price over the past 3 months compared to the US market

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Estrella Immunopharma, Inc. Competitors

Actinium Pharmaceuticals

NYSEAM:ATNM

US$40.9m

ImmuCell

NasdaqCM:ICCC

US$46.1m

Chemomab Therapeutics

NasdaqCM:CMMB

US$41.9m

CASI Pharmaceuticals

NasdaqCM:CASI

US$43.0m

Price History & Performance

Summary of share price highs, lows and changes for Estrella Immunopharma
Historical stock prices
Current Share Price	US$1.11
52 Week High	US$3.23
52 Week Low	US$0.63
Beta	0.43
1 Month Change	-19.57%
3 Month Change	32.46%
1 Year Change	-9.75%
3 Year Change	-88.80%
5 Year Change	n/a
Change since IPO	-88.62%

Recent updates

Companies Like Estrella Immunopharma (NASDAQ:ESLA) Are In A Position To Invest In Growth

Oct 09

Shareholder Returns

	ESLA	US Biotechs	US Market
7D	-10.5%	-0.1%	-0.5%
1Y	-9.7%	-6.4%	23.2%

Return vs Industry: ESLA underperformed the US Biotechs industry which returned -7% over the past year.

Return vs Market: ESLA underperformed the US Market which returned 23% over the past year.

Price Volatility

Is ESLA's price volatile compared to industry and market?
ESLA volatility
ESLA Average Weekly Movement	13.2%
Biotechs Industry Average Movement	11.1%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: ESLA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ESLA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2006	n/a	Cheng Liu	www.estrellabio.com

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103.

Estrella Immunopharma, Inc. Fundamentals Summary

How do Estrella Immunopharma's earnings and revenue compare to its market cap?
ESLA fundamental statistics
Market cap	US$40.16m
Earnings (TTM)	-US$8.82m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-4.6x

P/E Ratio

Is ESLA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ESLA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$8.82m
Earnings	-US$8.82m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.24
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ESLA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 12:08
End of Day Share Price	2025/01/08 00:00
Earnings	2024/09/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Estrella Immunopharma, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution